Stocks: Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) Raised to Strong-Buy at Zacks Investment Research

Stocks: Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) Raised to Strong-Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) from a hold rating to a strong-buy rating in a research report report published on Tuesday. They currently have $10.00 target price on the stock.

According to Zacks, “Avadel Pharmaceuticals plc is a specialty pharmaceutical company. Its product pipeline consists of hospital and paediatrics. Hospital segment provides Bloxiverz(R), Vazculep(R) and Akovaz(TM). Paediatrics segment provides Karbinal (TM) ER, AcipHex(R) Sprinkle and Flexichamber(TM). The company operates primarily in Ireland, USA and France. Avadel Pharmaceuticals plc, formerly known as Flamel Technologies SA, is headquartered in Lyon, France. “

Separately, TheStreet lowered Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a c- rating to a d- rating in a research note on Tuesday, March 7th.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) opened at 9.99 on Tuesday. The firm’s market capitalization is $413.39 million. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a 12-month low of $8.61 and a 12-month high of $15.45. The company’s 50-day moving average price is $9.51 and its 200-day moving average price is $10.08.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) last issued its quarterly earnings results on Tuesday, May 9th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.19. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share had a return on equity of 19.35% and a net margin of 18.25%. The business had revenue of $52.50 million for the quarter, compared to analyst estimates of $46.01 million. The business’s revenue for the quarter was up 45.0% compared to the same quarter last year. Equities analysts expect that Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share will post $0.35 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the stock. US Bancorp DE bought a new position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the first quarter valued at $121,000. State Street Corp bought a new position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the fourth quarter valued at $316,000. Knott David M bought a new position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the fourth quarter valued at $1,035,000. Russell Investments Group Ltd. bought a new position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the first quarter valued at $3,654,000. Finally, Perceptive Advisors LLC bought a new position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the fourth quarter valued at $14,424,000. 71.18% of the stock is currently owned by hedge funds and other institutional investors.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share Company Profile

Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.

Get a free copy of the Zacks research report on Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment